Malecare, America’s largest men’s cancer support network, this week announced the world’s first prostate cancer patient conference to feature an all-female faculty featuring twelve of the U.S.A.’s top prostate cancer clinicians. The Prostate Cancer Patient Conference is a day-long event taking place in New York City on October 5th. “Less than 1% of all [...]
Erleada (apalutamide) has just received FDA approval as a drug for treating men with non-metastatic castration-resistant prostate cancer. The proper pronunciation is Er ( Errr), (Like Her without the h) ) (lee) (long E) da. Now, repeat after me, "Erleada!" It's a pill that you take - I believe - four times a [...]
Non-Metastatic Castrate Resistant Prostate Cancer (nmCRPC) usually leads to metastatic prostate cancer and death. There are no approved treatments for nmCRPC. Apalutamide is a taken-by-mouth androgen receptor inhibitor with antitumor activity in CRPC. There's a much talked and written about clinical trial called, SPARTAN, that investigated how well Apalutamide works on maintaining metastasis-free survival (MFS) [...]
There have been numerous studies examining the how hormone deprivation (ADT), in the treatment of prostate cancer, has on a man’s cognition. There have been contradictor studies about this issue, however having had the experience and the honor of dealing with so many men with prostate cancer treated with androgen deprivation therapy (ADT), as well [...]
Prostate cancer treatment will change as we incorporate new studies into our clinical practice. One of the major emerging new trends is the earlier use of chemotherapy with androgen therapy (ADT) in men, including men who are still hormone responsive. This changing trend comes from the results from there pivotal randomized phase III trials: GETUG15, [...]
Randomized trials have clearly demonstrated that when low dose Prednisone (P) is combined with docetaxel chemotherapy (D) to treat prostate cancer there is a survival benefit. What is the role of the prednisone and does it actually provide any additional benefit to the docetaxel treatment itself? To answer this question a retrospective study was performed [...]
Researchers at the Duke Cancer Institute along with other cancer centers, in the largest analysis of its kind have found that the organ site where prostate cancer spreads has a direct impact on a man’s survival. They found that men with lymph-only metastasis statistically have the longest overall survival possibility, while those with liver involvement [...]
Because of the large amount of prostate cancer screening there has been a major shift in initial staging in prostate cancer in western countries, with the incidence of metastases at diagnosis decreasing from over 50% in the 1970s to currently less than 10%. Despite this very significant drop in late stage diagnoses prostate cancer is [...]
In an analysis of outcomes reported in the Journal of Clinical Oncology, men who were diagnosed with lymph node-positive prostate cancer (no bone involvement) who went on to receive targeted radiation (adjuvant radiotherapy) enjoyed a survival benefit over those individuals who did not have this therapy. This finding was specifically for men with both low-volume [...]
Men who develop bone metastases have often been viewed as having developed a significant negative change that prognosticates a negative impact on both their quality of life and on their survival. Contradicting this commonly held belief has been some research which has identified a subgroup of men with advanced prostate cancer with bone metastases who [...]
